# Safety and Efficacy of Oral GKT137831 in Patient With Type 2 Diabetes and Albuminuria

Study · id `cardio:ct-nct02010242` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02010242](<https://clinicaltrials.gov/study/NCT02010242>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT02010242

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 136 participants.

## Technical summary

Registry record NCT02010242. Randomized; quadruple masking; primary purpose treatment. Start 2013-10 (registry gives no type); primary completion 2015-02 (actual). Results posted on 2025-02-28.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 136 participants (enrolled count; ClinicalTrials.gov record NCT02010242, source copy `cardio:ctgov-nct02010242-2025-02-28`, retrieved 2026-11-18)
- Start date: 2013-10 (registry gives no type) (ClinicalTrials.gov record NCT02010242, source copy `cardio:ctgov-nct02010242-2025-02-28`, retrieved 2026-11-18)
- Primary completion: 2015-02 (actual) (ClinicalTrials.gov record NCT02010242, source copy `cardio:ctgov-nct02010242-2025-02-28`, retrieved 2026-11-18)
- Completion: 2015-03 (actual) (ClinicalTrials.gov record NCT02010242, source copy `cardio:ctgov-nct02010242-2025-02-28`, retrieved 2026-11-18)
- Results first posted: 2025-02-28 (ClinicalTrials.gov record NCT02010242, source copy `cardio:ctgov-nct02010242-2025-02-28`, retrieved 2026-11-18)
- Countries: United States; Australia; Canada; Czechia; Germany; Poland (ClinicalTrials.gov record NCT02010242, source copy `cardio:ctgov-nct02010242-2025-02-28`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02010242-2025-02-28`, retrieved 2026-11-18)

## The registry's words

- Brief title: Safety and Efficacy of Oral GKT137831 in Patient With Type 2 Diabetes and Albuminuria
- Condition: Type 2 Diabetes Mellitus With Diabetic Nephropathy
- Intervention (Drug): GKT137831
- Intervention (Drug): Placebo
- Lead sponsor: Asahi Kasei Therapeutics, AB
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)

## Provenance

Content hash: 679df41ed2a5f1b4e2b9df5cdb0af8485c2bebc4e13b9fcb1521712ecbfd1328
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
